A randomized, open-label, Phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors.

TPS2622 Background: Therapeutic decision for most cancers is mainly based on primary disease site, histological type and/or tumor burden. However, genotype-driven clinical trials where treatments are adapted to the molecular alteration supposed to drive tumor progression have recently emerged with promising early results (e.g. BATTLE, SAPHIR01/02, SHIVA, ...). Methods: MOST (My Own Specific Therapy) is a multicenter, randomized, open-label, adaptive phase II trial conducted in patients (pts) with progressive solid tumors (any subtype) after at least one prior therapy in the advanced setting. This trial aims to evaluate the clinical benefit of maintenance therapy targeting molecular alterations identified in the patient’s tumor. Primary endpoint is progression-free survival. Secondary endpoints include toxicity, objective response rate (RECIST1.1) and overall survival. Based on the presence of molecular alterations detected by a previous tumor molecular profiling, pts are treated with one of the following ...